Handelsavisen
prelaunch
Companies ›Healthcare ›TTI.V
TT
TTI.V — TSX Venture Biotechnology & Medical Research

Thiogenesis Therapeutics, Corp.

$0,60
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$10,42
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

TTI.V operates in the healthcare diagnostics industry, providing products and services related to diagnostic testing and medical research.

Business. TTI.V is a biotechnology and medical research company focused on healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, generating revenue through product sales. It is listed on the TSX Venture Exchange under the ticker TTI.V. Specific details regarding operating segments, headquarters location, and geographic presence are not available in the provided data.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
BUY5 analysts
4 buy1 hold0 sell
Avg 12m price target12,20

Analyst recommendations

5 analysts · consensus Buy
Buy4
Hold1
Sell0
12-month price target
12,20
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
5 analysts · indicative
Ownership→
JANUS HENDERSON GROUP PLC
largest disclosed fund holder
Profitability
—
not yet wired
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning TTI.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to TTI.V. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    TTI.V is a biotechnology and medical research company focused on healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, generating revenue through product sales. It is listed on the TSX Venture Exchange under the ticker TTI.V. Specific details regarding operating segments, headquarters location, and geographic presence are not available in the provided data.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    TTI.V maintains a strong liquidity position with $1.62 billion in cash and equivalents, significantly exceeding its total equity of $574.38 million, indicating a conservative capital structure with no debt. The company's debt-to-equity ratio is 0.0, reflecting a purely equity-funded balance sheet. However, the company reported negative operating cash flow of $6.03 million, suggesting potential challenges in generating cash from operations.

    In terms of profitability, TTI.V's financial performance is not yet benchmarkable against industry-specific metrics due to the absence of a defined industry_config for this company. The lack of a defined industry cohort prevents a direct comparison of profitability metrics such as ROIC or EBITDA margins to industry medians.

    TTI.V's revenue concentration and geographic exposure are not disclosed in the available data, limiting the ability to assess segment or regional risk. The company does not provide segment-level financials in the current dataset, and no competitor market share data is available for comparison.

    The company's growth trajectory is currently undefined, as no outlook data is available for the current or next fiscal year. Historical revenue data is also not provided, making it difficult to assess growth trends.

    TTI.V presents low liquidity and dilution risk, with no immediate filing-based flags detected. The company has no dilution potential in the basic shares outstanding, as diluted and basic shares are equal at 51.84 million. No adjustments were applied to the valuation metrics, indicating a clean capital structure.

    Recent events, including filings and transcripts, are not disclosed in the available data, preventing an assessment of recent operational or strategic developments.

    Key takeaways
    • TTI.V has a conservative capital structure with no debt and a large cash reserve.
    • The company's negative operating cash flow raises concerns about operational efficiency.
    • No industry-specific metrics are available for benchmarking profitability or returns.
    • TTI.V presents low liquidity and dilution risk, with no immediate flags detected.
    • The company's growth trajectory and geographic exposure are not disclosed in the available data.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $0,60
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    —
    Net cashⓘ
    $1.6M
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    —
    ROEⓘ
    —
    Cash conversionⓘ
    —
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships47 disclosed relationships · 3 types · extracted from filings & disclosures
    Customers2
    Partners1
    Standard Lithium LtdSLI.OPartner95%Source ↗
    Subsidiaries44
    EX21:07f3d5cc17b0EX21:07f3d5cc17b0Subsidiarie97%
    EX21:1309c0b38747EX21:1309c0b38747Subsidiarie97%
    EX21:15447c82f174EX21:15447c82f174Subsidiarie97%
    EX21:2798871bdb22EX21:2798871bdb22Subsidiarie97%
    EX21:28801fe4a6e6EX21:28801fe4a6e6Subsidiarie97%
    EX21:297c91152dceEX21:297c91152dceSubsidiarie97%
    EX21:2dc9d8cb16cdEX21:2dc9d8cb16cdSubsidiarie97%
    EX21:300e077bb3fcEX21:300e077bb3fcSubsidiarie97%
    EX21:37513b011ae7EX21:37513b011ae7Subsidiarie97%
    EX21:3b320f99187bEX21:3b320f99187bSubsidiarie97%
    EX21:3d9d11c9d39fEX21:3d9d11c9d39fSubsidiarie97%
    EX21:3dc7e0b74dc0EX21:3dc7e0b74dc0Subsidiarie97%
    EX21:490326fdf9a8EX21:490326fdf9a8Subsidiarie97%
    EX21:49107d9ec724EX21:49107d9ec724Subsidiarie97%
    EX21:495e54770fbeEX21:495e54770fbeSubsidiarie97%
    EX21:4a43ae7e53ebEX21:4a43ae7e53ebSubsidiarie97%
    EX21:4a7a6cfe01cfEX21:4a7a6cfe01cfSubsidiarie97%
    EX21:4c1f333cc082EX21:4c1f333cc082Subsidiarie97%
    EX21:59897065a626EX21:59897065a626Subsidiarie97%
    EX21:5e3ce9a1fa06EX21:5e3ce9a1fa06Subsidiarie97%
    EX21:5feb7266d869EX21:5feb7266d869Subsidiarie97%
    EX21:61db0c9f8c66EX21:61db0c9f8c66Subsidiarie97%
    EX21:650da2e966c1EX21:650da2e966c1Subsidiarie97%
    EX21:6d77a098a8ecEX21:6d77a098a8ecSubsidiarie97%
    EX21:77a9aa6e073dEX21:77a9aa6e073dSubsidiarie97%
    EX21:793ca2acc39fEX21:793ca2acc39fSubsidiarie97%
    EX21:8fde86d61165EX21:8fde86d61165Subsidiarie97%
    EX21:990accdbe19eEX21:990accdbe19eSubsidiarie97%
    EX21:9c0b0fe0658eEX21:9c0b0fe0658eSubsidiarie97%
    EX21:b27e211b2e73EX21:b27e211b2e73Subsidiarie97%
    EX21:bf3a62793707EX21:bf3a62793707Subsidiarie97%
    EX21:c39f2501fd7eEX21:c39f2501fd7eSubsidiarie97%
    EX21:c7c233f71a3bEX21:c7c233f71a3bSubsidiarie97%
    EX21:c8a4b4355c59EX21:c8a4b4355c59Subsidiarie97%
    EX21:ce4efef00d7dEX21:ce4efef00d7dSubsidiarie97%
    EX21:d18695da523fEX21:d18695da523fSubsidiarie97%
    EX21:d6b0837a99dcEX21:d6b0837a99dcSubsidiarie97%
    EX21:da1e7d3eb9e0EX21:da1e7d3eb9e0Subsidiarie97%
    EX21:da62247d1012EX21:da62247d1012Subsidiarie97%
    EX21:ee2d4b462a52EX21:ee2d4b462a52Subsidiarie97%
    EX21:ef32dfbe43ecEX21:ef32dfbe43ecSubsidiarie97%
    EX21:f2c622479f84EX21:f2c622479f84Subsidiarie97%
    EX21:fc2412a2f68dEX21:fc2412a2f68dSubsidiarie97%
    EX21:fcc2ce3cdba3EX21:fcc2ce3cdba3Subsidiarie97%

    Supply chain

    Vendors → TTI ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSTTITTIThiogenesis Therapeutics, Corp.47 entitiesStandard Lithium LtdUnclassifiedUSEog Resources IncOil & GasUSHALLIBURTON COMPANYOil & GasUS
    3 mentions in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$11,00
    Mean$12,20
    Median$11,50
    High$14,00
    Spot$0,60
    +1933.3 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    D/E0,00Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net disposed 987 310 sh14 exercises · 8 grants14 insiders
    • John Angela DDirector · Restricted Stock Units → Common StockDisposed 37 723exercise · 2026-06-12
    • GLICK JOHN FDirector · Restricted Stock Units → Common StockDisposed 51 441exercise · 2026-06-12
    • Garcia Christian ADirector · Restricted Stock Units → Common StockDisposed 37 723exercise · 2026-06-12
    • McGee Sharon D. BoothDirector · Restricted Stock Units → Common StockDisposed 37 723exercise · 2026-06-12
    • BATES THOMAS R JRDirector · Restricted Stock Units → Common StockDisposed 37 723exercise · 2026-06-12
    • Armour Joseph BryanSr Vice President · Restricted Stock Unit → Common StockAcquired 24 203grant · 2026-06-05
    • GLICK JOHN FDirector · Restricted Stock Units → Common StockAcquired 17 983grant · 2026-05-22
    • McGee Sharon D. BoothDirector · Restricted Stock Units → Common StockAcquired 13 987grant · 2026-05-22
    • SLOAT JULIA ADirector · Restricted Stock Units → Common StockAcquired 13 987grant · 2026-05-22
    • John Angela DDirector · Restricted Stock Units → Common StockAcquired 13 987grant · 2026-05-22
    • Garcia Christian ADirector · Restricted Stock Units → Common StockAcquired 13 987grant · 2026-05-22
    • Williams Shawn D.Director · Restricted Stock Units → Common StockAcquired 13 987grant · 2026-05-22
    • BATES THOMAS R JRDirector · Restricted Stock Units → Common StockAcquired 13 987grant · 2026-05-22
    • SANDERSON MATTHEWExecutive Vice President · Restricted Stock Units → Common StockDisposed 86 034exercise · 2026-03-14
    • Moeller Timothy CSVP - Supply Chain & Chemicals · Restricted Stock Units → Common StockDisposed 82 593exercise · 2026-03-14
    • SERRANO ELIJIO VSr. Vice President & CFO · Restricted Stock Units → Common StockDisposed 137 654exercise · 2026-03-14
    • Murphy Brady MPresident & CEO · Restricted Stock Units → Common StockDisposed 371 666exercise · 2026-03-14
    • Boston Shoemake Alicia rSr. VP and General Counsel · Restricted Stock Units → Common StockDisposed 33 037exercise · 2026-03-14
    • Moeller Timothy CSVP - Supply Chain & Chemicals · Restricted Stock Units → Common StockDisposed 27 198exercise · 2026-02-28
    • SANDERSON MATTHEWExecutive Vice President · Restricted Stock Units → Common StockDisposed 29 141exercise · 2026-02-28
    • Murphy Brady MPresident & CEO · Restricted Stock Units → Common StockDisposed 116 564exercise · 2026-02-28
    • McNiven RoySr. Vice President · Restricted Stock Units → Common StockDisposed 27 198exercise · 2026-02-28

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • TTI.V Market data — financials · 2026-05-29

    Ownership & reference

    Top holders

    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,25 %$514M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,25 %$1 343M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,22 %$486M
    • First Trust Advisors L.P.Investment Managers · as of 2026-03-310,11 %$160M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,06 %$304M
    • Invesco QQQ TrustFunds · as of 2026-03-310,06 %$361M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,05 %$730M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,04 %$165M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,04 %$1 742M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,04 %$1 093M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,04 %$195M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,03 %$108M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,03 %$259M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,03 %$117M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,03 %$60M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,03 %$2 035M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,03 %$0M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,03 %$178M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,02 %$140M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,02 %$36M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,02 %$41M
    • FMR LLCInstitutional Investor · as of 2026-03-310,02 %$313M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,01 %$243M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,01 %$54M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,01 %$46M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,01 %$68M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,01 %$28M
    • Fisher InvestmentsInvestment Managers · as of 2026-03-310,01 %$20M
    • EATON VANCE MANAGEMENTInstitutional Investor · as of 2022-09-300,01 %$0M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$7M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$3M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$2M

    Insider activity

    Net selling1 buys · 2 sellsnet -$320K12 insiders · last 365d
    • Murphy Brady MPresident & CEO · Common StockSold 61 @ $10,01$610 · 2026-07-02
    • Murphy Brady MPresident & CEO · Common StockSold 50 000 @ $10,72$536K · 2026-07-01
    • John Angela DDirector · Common StockOther 37 723 · 2026-06-12
    • McGee Sharon D. BoothDirector · Common StockOther 37 723 · 2026-06-12
    • Garcia Christian ADirector · Common StockOther 37 723 · 2026-06-12
    • GLICK JOHN FDirector · Common StockOther 51 441 · 2026-06-12
    • BATES THOMAS R JRDirector · Common StockOther 37 723 · 2026-06-12
    • Hallead KurtVP-Treasurer & IR · Common StockBought 22 000 @ $9,86$217K · 2026-06-09
    • Moeller Timothy CSVP - Supply Chain & Chemicals · Common StockOther 82 593 · 2026-03-14
    • Moeller Timothy CSVP - Supply Chain & Chemicals · Common StockOther 37 043 @ $8,22$304K · 2026-03-14
    • SERRANO ELIJIO VSr. Vice President & CFO · Common StockOther 137 654 · 2026-03-14
    • SERRANO ELIJIO VSr. Vice President & CFO · Common StockOther 54 167 @ $8,22$445K · 2026-03-14
    • Murphy Brady MPresident & CEO · Common StockOther 371 666 · 2026-03-14
    • Murphy Brady MPresident & CEO · Common StockOther 157 401 @ $8,22$1,3M · 2026-03-14
    • SANDERSON MATTHEWExecutive Vice President · Common StockOther 86 034 · 2026-03-14
    • SANDERSON MATTHEWExecutive Vice President · Common StockOther 38 157 @ $8,22$314K · 2026-03-14
    • Boston Shoemake Alicia rSr. VP and General Counsel · Common StockOther 33 037 · 2026-03-14
    • Boston Shoemake Alicia rSr. VP and General Counsel · Common StockOther 13 001 @ $8,22$107K · 2026-03-14
    • McNiven RoySr. Vice President · Common StockOther 50 000 · 2026-03-11
    • Moeller Timothy CSVP - Supply Chain & Chemicals · Common StockOther 27 198 · 2026-02-28
    • Moeller Timothy CSVP - Supply Chain & Chemicals · Common StockOther 12 199 @ $8,66$106K · 2026-02-28
    • McNiven RoySr. Vice President · Common StockOther 27 198 · 2026-02-28
    • McNiven RoySr. Vice President · Common StockOther 10 703 @ $8,66$93K · 2026-02-28
    • Murphy Brady MPresident & CEO · Common StockOther 116 564 · 2026-02-28
    • Murphy Brady MPresident & CEO · Common StockOther 49 365 @ $8,66$428K · 2026-02-28

    Short positioning

    10.0Mshares short+8.7% vs prior
    6.79days to cover
    58.6%short of daily vol
    92fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    TTI.VCanonical
    TSX Venture · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.
    Relationship graph
    TTIEOG.OHAL.NSLI.OEX21:07fEX21:130EX21:154EX21:279EX21:288EX21:297EX21:2dcBiotechnology
    This companySectorCustomersPartnersSubsidiaries

    Evidence & claims

    From filings & derived data
    • Return on equity (FY 2025-12-31): 1.1%Derived (calculated)
    • Return on assets (FY 2025-12-31): 0.4%Derived (calculated)
    • Current ratio (FY 2025-12-31): 1.96xDerived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 33.2%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 96.4%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -97.6%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -97.6%Derived (calculated)
    • Gross profit (YoY) (2025-12-31 vs 2024-12-31): 11.5%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 5.7%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -97.2%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 174.8%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 11.5%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 11.7%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 2.4%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 11.0%Derived (calculated)
    • Net income (annual): USD 3MSEC XBRL filing
    • Cash & equivalents (annual): USD 72.63MSEC XBRL filing
    • Long-term debt (annual): USD 190MSEC XBRL filing
    • Cost of revenue (annual): USD 433.72MSEC XBRL filing
    • Current liabilities (annual): USD 161.21MSEC XBRL filing
    • Current assets (annual): USD 316.68MSEC XBRL filing
    • Total assets (annual): USD 675.76MSEC XBRL filing
    • Gross profit (annual): USD 155.95MSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES 0SEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-08-03 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
    2026-07-02INSIDERMurphy Brady M sold 61 sh — President & CEO ~$1k
    2026-07-01INSIDERMurphy Brady M sold 50.0k sh — President & CEO ~$536k
    2026-06-15FILING8-K filing →
    2026-06-12 00:00 UTCINSIDER12 insider transactions — 2026-06 · net buy $217k 6 derivative
    2026-06-12INSIDERJohn Angela D transacted 37.7k sh — Director
    2026-06-12INSIDERMcGee Sharon D. Booth transacted 37.7k sh — Director
    2026-06-12INSIDERGarcia Christian A transacted 37.7k sh — Director
    2026-06-12INSIDERGLICK JOHN F transacted 51.4k sh — Director
    2026-06-12INSIDERBATES THOMAS R JR transacted 37.7k sh — Director
    2026-06-12INSIDERJohn Angela D disposed of 37.7k sh Restricted Stock Units — Director
    2026-06-12INSIDERMcGee Sharon D. Booth disposed of 37.7k sh Restricted Stock Units — Director
    2026-06-12INSIDERGarcia Christian A disposed of 37.7k sh Restricted Stock Units — Director
    2026-06-12INSIDERGLICK JOHN F disposed of 51.4k sh Restricted Stock Units — Director
    2026-06-12INSIDERBATES THOMAS R JR disposed of 37.7k sh Restricted Stock Units — Director
    2026-06-09INSIDERHallead Kurt bought 22.0k sh — VP-Treasurer & IR ~$217k
    2026-06-05INSIDERArmour Joseph Bryan acquired 24.2k sh Restricted Stock Unit — Sr Vice President
    2026-06-04FILING8-K filing →
    2026-06-04FILING424B5 filing →
    2026-06-02FILING8-K filing →
    2026-06-02FILING424B5 filing →
    2026-05-26FILING8-K filing →
    2026-05-22 00:00 UTCINSIDER7 insider transactions — 2026-05 7 derivative
    2026-05-22INSIDERGLICK JOHN F acquired 18.0k sh Restricted Stock Units — Director
    2026-05-22INSIDERJohn Angela D acquired 14.0k sh Restricted Stock Units — Director
    2026-05-22INSIDERGarcia Christian A acquired 14.0k sh Restricted Stock Units — Director
    2026-05-22INSIDERMcGee Sharon D. Booth acquired 14.0k sh Restricted Stock Units — Director
    2026-05-22INSIDERBATES THOMAS R JR acquired 14.0k sh Restricted Stock Units — Director
    2026-05-22INSIDERWilliams Shawn D. acquired 14.0k sh Restricted Stock Units — Director
    2026-05-22INSIDERSLOAT JULIA A acquired 14.0k sh Restricted Stock Units — Director
    2026-04-29FILING10-Q filing →
    2026-04-29FILING8-K filing →
    2026-04-09FILINGDEF 14A filing →
    2026-03-14 00:00 UTCINSIDER16 insider transactions — 2026-03 · net sell $2.5M 5 derivative
    2026-03-14INSIDERMoeller Timothy C transacted 82.6k sh — SVP - Supply Chain & Chemicals
    2026-03-14INSIDERMoeller Timothy C transacted 37.0k sh — SVP - Supply Chain & Chemicals ~$304k
    2026-03-14INSIDERSERRANO ELIJIO V transacted 137.7k sh — Sr. Vice President & CFO
    2026-03-14INSIDERSERRANO ELIJIO V transacted 54.2k sh — Sr. Vice President & CFO ~$445k
    2026-03-14INSIDERMurphy Brady M transacted 371.7k sh — President & CEO
    Showing the 40 most recent of 58 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage